Medical Affairs 2025 – Excellence in the era of precision medicine

pharmafile | May 15, 2019 | News story | Medical Communications, Research and Development |  pharma, veeva 

Medical affairs is at the leading edge of a trend. As the life sciences industry shifts towards precision medicine, its investment in medical and scientific affairs has steadily increased. From 2014 to 2016, MSL teams grew by 12% overall, and 31% in specialty areas such as oncology.

The success of these MSLs hinges on greater scientific insights, deeper collaboration, and a focus on tangible medical outcomes. Leading organisations are reinventing their medical affairs functions to meet the needs of this new era.

“In the life sciences industry, we see a shift toward transparency and collaboration,” says Robert Groebel, Vice President of Medical Strategy at Veeva Systems, the leader in cloud-based software for the global life sciences industry. “Medical affairs has a unique opportunity to add greater value to the journey.”

Medical affairs leaders from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations share their perspectives on key challenges impacting medical affairs and a roadmap for success in the coming decade in a new report: “Medical Affairs 2025”. Organisations will better understand how their peers address challenges today and how to transform medical affairs into a leading function within the company.  Access the full report here.